Contravir Pharmaceut (CTRV) 2.87 $CTRV
ContraVir Pharmaceuticals prices public offering at a fixed combined price of USD3.00
M2 - Thu Oct 08, 4:09AM CDT
Biopharmaceutical company ContraVir Pharmaceuticals (NasdaqCM:CTRV) said on Wednesday that it has priced an underwritten public offering of 5,000,000 shares of its common stock and warrants to purchase up to 3,000,000 shares of its common stock at a fixed combined price to the public of USD3.00.
CTRV: 2.87 (-0.02)
ContraVir Pharmaceuticals (CTRV) Stock Drops After Pricing Secondary Offering
at The Street - Wed Oct 07, 10:05AM CDT
ContraVir Pharmaceuticals (CTRV) shares are down over 15% after the company priced its secondary offering of 5 million shares at $3 per share.
CTRV: 2.87 (-0.02)
ContraVir Pharmaceuticals, Inc. Pricing Underwritten Public Offering Of Common Stock
PR Newswire - Wed Oct 07, 8:04AM CDT
ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV) ("ContraVir" or the "Company"
, a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock and warrants to purchase up to 3,000,000 shares of the Company's common stock at a fixed combined price to the public of $3.00. The shares of common stock and warrants will be issued separately. The warrants will be exercisable for a period of five years following the issuance thereof at an exercise price of $4.25 per share. There is no established public trading market for the warrants and ContraVir does not expect a market to develop in the future. ContraVir has also granted to the underwriters a 45-day option to purchase up to an additional 750,000 shares of its common stock and warrants to purchase up to 450,000 shares of common stock to cover overallotments in connection with the offering. The gross proceeds to ContraVir from this offering are expected to be $15,000,000, before deducting the underwriting discount and other estimated offering expenses payable by the Company, and assuming no exercise of the overallotment option. The offering is expected to close on or about October 13, 2015, subject to customary closing conditions.
CTRV: 2.87 (-0.02)
Pharmaceutical Sector Due Diligence Report - Searching for Opportunities Among the Bruised Small Cap Market
ACCESSWIRE - Wed Oct 07, 7:14AM CDT
NEW YORK, NY / ACCESSWIRE / October 7, 2015 / We profile four development stage companies with exciting prospects for future growth. In the report, we describe the companies, their products and provide recommendations on which have the better prospects to realize their growth potential.
CTRV: 2.87 (-0.02), TROV: 5.72 (+0.11), TLOG: 2.01 (+0.08), KERX: 4.25 (+0.23)
ContraVir Pharmaceuticals proposes public offering of common stock and warrants
M2 - Wed Oct 07, 3:02AM CDT
Biopharmaceutical company ContraVir Pharmaceuticals (NasdaqCM:CTRV) said on Tuesday that it plans to issue shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering.
CTRV: 2.87 (-0.02)
ContraVir Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
PR Newswire - Tue Oct 06, 3:08PM CDT
ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV) ("ContraVir" or the "Company", a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, today announced that it intends to offer shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
CTRV: 2.87 (-0.02)
ContraVir Soars 150% as New HBV Drug is 60x More Active than Gilead's Viread
Andrew Steele - Zacks Investment Research - Mon Oct 05, 11:57AM CDT
ContraVir Pharmaceuticals announced earlier today that one of its drugs is more active than a drug produced by Gilead Sciences. Because of this, stock prices are up on the day.
CTRV: 2.87 (-0.02), GILD: 100.65 (-0.16)
ContraVir Reports New Data demonstrating CMX157 to be 60-Fold More Potent Against Hepatitis B Virus than Gilead's Viread®
PR Newswire - Mon Oct 05, 5:00AM CDT
ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, today announced preliminary data dramatizing the unique properties of CMX157, the Company's highly potent lipid prodrug of the successful antiviral drug tenofovir (TFV). CMX157 was shown to be 60-fold more active than tenofovir against the hepatitis B virus (HBV) based on in vitro studies. This significant potency difference has considerable potential in increasing the safety profile and reducing the side effects compared to tenofovir DF (Viread®).
CTRV: 2.87 (-0.02)
BioWatch's Alan Leong Interviewed by The Life Sciences Report
Marketwired - Thu Sep 10, 8:02AM CDT
CAR T-cell therapies show potential in treating acute myeloid leukemia (AML) and other medical conditions, but there's a lot of work to do before they're ready for commercialization. Alan Leong, senior analyst with BioWatch, updates The Life Sciences Report about the current state of CAR T-cell therapeutics and how some companies are developing bispecific antibodies.
CPXX: 1.83 (unch), CTRV: 2.87 (-0.02), SNSS: 0.93 (unch), RP.VN: 0.350 (+0.010)
ContraVir to Present at Rodman & Renshaw 17th Annual Global Investment Conference
PR Newswire - Tue Sep 01, 3:05PM CDT
ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it will present at the Rodman & Renshaw 17th Annual Global Investment Conference sponsored by H.C. Wainwright & Co. taking place September 8-10, 2015 at The St. Regis Hotel in New York, NY.
CTRV: 2.87 (-0.02)
ContraVir Presentation Now Available for On-Demand Viewing
CNW Group - Wed Aug 12, 7:00AM CDT
Company invites individual and institutional investors to login at VirtualInvestorConferences.com
CTRV: 2.87 (-0.02)
Nasdaq Companies to Present Online to Investors on August 6
PR Newswire - Tue Aug 04, 7:32AM CDT
VirtualInvestorsConferences.com host CEOs and senior executives: live questions answered during online roadshow and in virtual trade booths
CTRV: 2.87 (-0.02), PULM: 4.75 (-0.15), IMNP: 1.28 (+0.02), PSEC: 7.63 (+0.06)
ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com
CNW Group - Tue Aug 04, 7:30AM CDT
ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, today announced that James Sapirstein, Chief Executive Officer, will present live at VirtualInvestorConferences.com on August 6, 2015.
CTRV: 2.87 (-0.02)
ContraVir Pharmaceuticals Enrolls First Patient in Pivotal Phase 3 Study of FV-100 for Treatment of Shingles and Shingles-Associated Pain
PR Newswire - Mon Aug 03, 5:00AM CDT
ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the first patient has been enrolled in the Company's pivotal Phase 3 clinical study, study 007, of FV-100 to prevent the debilitating shingles-associated pain known as post-herpetic neuralgia (PHN). The first patient in the study enrolled at Center for Clinical Studies in Houston, Texas. The study will build upon prior clinical results for FV-100, including Phase 1 trials and a large Phase 2 clinical trial in shingles patients, which demonstrated favorable safety and tolerability for FV-100.
CTRV: 2.87 (-0.02)
ContraVir to Present at Cantor Fitzgerald Inaugural Healthcare Conference
PR Newswire - Wed Jul 01, 3:05PM CDT
ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it will present at the Cantor Fitzgerald Inaugural Healthcare Conference taking place in New York, NY on July 8, 2015 at Le Parker Meridien Hotel.
CTRV: 2.87 (-0.02)
ContraVir CEO James Sapirstein Appointed to BIO's ECS Board of Directors and BioNJ's Board of Trustees
PR Newswire - Mon Jun 15, 4:15PM CDT
ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today the appointment of ContraVir CEO James Sapirstein to the Biotechnology Industry Organization (BIO) Emerging Companies Section Governing Board (ECSGB) and the Capital Formation Committee. Additionally, Mr. Sapirstein has been appointed to the Board of Trustees of BioNJ, a network of approximately 400 member companies representing research-based life sciences companies and stakeholders in New Jersey.
CTRV: 2.87 (-0.02), TBRA: 10.56 (-0.63)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jun 15, 11:47AM CDT
CTRV: 2.87 (-0.02), ZA: 1.40 (-0.01), SWSH: 1.17 (-0.06), ATRA: 32.28 (+0.20), ORPN: 5.14 (-0.19), ARDX: 20.70 (+0.66), DSKY: 11.72 (+0.14), IVTY: 12.53 (+0.35), CACQ: 7.67 (-0.04), CI: 136.36 (+2.73), AMCN: 5.52 (+0.01), SKYS: 6.05 (-0.02), AST: 4.70 (-0.01), ATV: 0.67 (+0.01), INPH: 0.04 (unch), CTP: 1.36 (unch), CBLI: 4.53 (+0.07), RTGN: 5.06 (+1.01), ERN: 4.73 (+0.01), KONE: 4.13 (+0.08)
ContraVir Pharmaceuticals prices public offering at a fixed combined price of USD3.00
M2 - Thu Oct 08, 4:09AM CDT
Biopharmaceutical company ContraVir Pharmaceuticals (NasdaqCM:CTRV) said on Wednesday that it has priced an underwritten public offering of 5,000,000 shares of its common stock and warrants to purchase up to 3,000,000 shares of its common stock at a fixed combined price to the public of USD3.00.
CTRV: 2.87 (-0.02)
ContraVir Pharmaceuticals (CTRV) Stock Drops After Pricing Secondary Offering
at The Street - Wed Oct 07, 10:05AM CDT
ContraVir Pharmaceuticals (CTRV) shares are down over 15% after the company priced its secondary offering of 5 million shares at $3 per share.
CTRV: 2.87 (-0.02)
ContraVir Pharmaceuticals, Inc. Pricing Underwritten Public Offering Of Common Stock
PR Newswire - Wed Oct 07, 8:04AM CDT
ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV) ("ContraVir" or the "Company"
, a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock and warrants to purchase up to 3,000,000 shares of the Company's common stock at a fixed combined price to the public of $3.00. The shares of common stock and warrants will be issued separately. The warrants will be exercisable for a period of five years following the issuance thereof at an exercise price of $4.25 per share. There is no established public trading market for the warrants and ContraVir does not expect a market to develop in the future. ContraVir has also granted to the underwriters a 45-day option to purchase up to an additional 750,000 shares of its common stock and warrants to purchase up to 450,000 shares of common stock to cover overallotments in connection with the offering. The gross proceeds to ContraVir from this offering are expected to be $15,000,000, before deducting the underwriting discount and other estimated offering expenses payable by the Company, and assuming no exercise of the overallotment option. The offering is expected to close on or about October 13, 2015, subject to customary closing conditions. CTRV: 2.87 (-0.02)
Pharmaceutical Sector Due Diligence Report - Searching for Opportunities Among the Bruised Small Cap Market
ACCESSWIRE - Wed Oct 07, 7:14AM CDT
NEW YORK, NY / ACCESSWIRE / October 7, 2015 / We profile four development stage companies with exciting prospects for future growth. In the report, we describe the companies, their products and provide recommendations on which have the better prospects to realize their growth potential.
CTRV: 2.87 (-0.02), TROV: 5.72 (+0.11), TLOG: 2.01 (+0.08), KERX: 4.25 (+0.23)
ContraVir Pharmaceuticals proposes public offering of common stock and warrants
M2 - Wed Oct 07, 3:02AM CDT
Biopharmaceutical company ContraVir Pharmaceuticals (NasdaqCM:CTRV) said on Tuesday that it plans to issue shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering.
CTRV: 2.87 (-0.02)
ContraVir Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
PR Newswire - Tue Oct 06, 3:08PM CDT
ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV) ("ContraVir" or the "Company"
, a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, today announced that it intends to offer shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. CTRV: 2.87 (-0.02)
ContraVir Soars 150% as New HBV Drug is 60x More Active than Gilead's Viread
Andrew Steele - Zacks Investment Research - Mon Oct 05, 11:57AM CDT
ContraVir Pharmaceuticals announced earlier today that one of its drugs is more active than a drug produced by Gilead Sciences. Because of this, stock prices are up on the day.
CTRV: 2.87 (-0.02), GILD: 100.65 (-0.16)
ContraVir Reports New Data demonstrating CMX157 to be 60-Fold More Potent Against Hepatitis B Virus than Gilead's Viread®
PR Newswire - Mon Oct 05, 5:00AM CDT
ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, today announced preliminary data dramatizing the unique properties of CMX157, the Company's highly potent lipid prodrug of the successful antiviral drug tenofovir (TFV). CMX157 was shown to be 60-fold more active than tenofovir against the hepatitis B virus (HBV) based on in vitro studies. This significant potency difference has considerable potential in increasing the safety profile and reducing the side effects compared to tenofovir DF (Viread®).
CTRV: 2.87 (-0.02)
BioWatch's Alan Leong Interviewed by The Life Sciences Report
Marketwired - Thu Sep 10, 8:02AM CDT
CAR T-cell therapies show potential in treating acute myeloid leukemia (AML) and other medical conditions, but there's a lot of work to do before they're ready for commercialization. Alan Leong, senior analyst with BioWatch, updates The Life Sciences Report about the current state of CAR T-cell therapeutics and how some companies are developing bispecific antibodies.
CPXX: 1.83 (unch), CTRV: 2.87 (-0.02), SNSS: 0.93 (unch), RP.VN: 0.350 (+0.010)
ContraVir to Present at Rodman & Renshaw 17th Annual Global Investment Conference
PR Newswire - Tue Sep 01, 3:05PM CDT
ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it will present at the Rodman & Renshaw 17th Annual Global Investment Conference sponsored by H.C. Wainwright & Co. taking place September 8-10, 2015 at The St. Regis Hotel in New York, NY.
CTRV: 2.87 (-0.02)
ContraVir Presentation Now Available for On-Demand Viewing
CNW Group - Wed Aug 12, 7:00AM CDT
Company invites individual and institutional investors to login at VirtualInvestorConferences.com
CTRV: 2.87 (-0.02)
Nasdaq Companies to Present Online to Investors on August 6
PR Newswire - Tue Aug 04, 7:32AM CDT
VirtualInvestorsConferences.com host CEOs and senior executives: live questions answered during online roadshow and in virtual trade booths
CTRV: 2.87 (-0.02), PULM: 4.75 (-0.15), IMNP: 1.28 (+0.02), PSEC: 7.63 (+0.06)
ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com
CNW Group - Tue Aug 04, 7:30AM CDT
ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, today announced that James Sapirstein, Chief Executive Officer, will present live at VirtualInvestorConferences.com on August 6, 2015.
CTRV: 2.87 (-0.02)
ContraVir Pharmaceuticals Enrolls First Patient in Pivotal Phase 3 Study of FV-100 for Treatment of Shingles and Shingles-Associated Pain
PR Newswire - Mon Aug 03, 5:00AM CDT
ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the first patient has been enrolled in the Company's pivotal Phase 3 clinical study, study 007, of FV-100 to prevent the debilitating shingles-associated pain known as post-herpetic neuralgia (PHN). The first patient in the study enrolled at Center for Clinical Studies in Houston, Texas. The study will build upon prior clinical results for FV-100, including Phase 1 trials and a large Phase 2 clinical trial in shingles patients, which demonstrated favorable safety and tolerability for FV-100.
CTRV: 2.87 (-0.02)
ContraVir to Present at Cantor Fitzgerald Inaugural Healthcare Conference
PR Newswire - Wed Jul 01, 3:05PM CDT
ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it will present at the Cantor Fitzgerald Inaugural Healthcare Conference taking place in New York, NY on July 8, 2015 at Le Parker Meridien Hotel.
CTRV: 2.87 (-0.02)
ContraVir CEO James Sapirstein Appointed to BIO's ECS Board of Directors and BioNJ's Board of Trustees
PR Newswire - Mon Jun 15, 4:15PM CDT
ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today the appointment of ContraVir CEO James Sapirstein to the Biotechnology Industry Organization (BIO) Emerging Companies Section Governing Board (ECSGB) and the Capital Formation Committee. Additionally, Mr. Sapirstein has been appointed to the Board of Trustees of BioNJ, a network of approximately 400 member companies representing research-based life sciences companies and stakeholders in New Jersey.
CTRV: 2.87 (-0.02), TBRA: 10.56 (-0.63)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jun 15, 11:47AM CDT
CTRV: 2.87 (-0.02), ZA: 1.40 (-0.01), SWSH: 1.17 (-0.06), ATRA: 32.28 (+0.20), ORPN: 5.14 (-0.19), ARDX: 20.70 (+0.66), DSKY: 11.72 (+0.14), IVTY: 12.53 (+0.35), CACQ: 7.67 (-0.04), CI: 136.36 (+2.73), AMCN: 5.52 (+0.01), SKYS: 6.05 (-0.02), AST: 4.70 (-0.01), ATV: 0.67 (+0.01), INPH: 0.04 (unch), CTP: 1.36 (unch), CBLI: 4.53 (+0.07), RTGN: 5.06 (+1.01), ERN: 4.73 (+0.01), KONE: 4.13 (+0.08)
